Pioneering Research Suggests Menstrual Blood Test as Convenient Alternative to Cervical Cancer Screening
In a groundbreaking study published in the BMJ medical journal, researchers have discovered that testing menstrual blood for signs of cervical cancer could be a game-changer in women's health. The innovative approach involves using a sanitary pad with a blood sample strip to detect human papillomavirus (HPV), which is responsible for most cases of cervical cancer.
Contrary to traditional methods where women undergo cervical screening under the care of a clinician, who collects a sample via a brush inserted into the vagina, this new test could provide a convenient and non-invasive alternative. According to the study, the menstrual blood test showed remarkable sensitivity and specificity in detecting cervical cell abnormalities (CIN2 and CIN3), with a 94.7% accuracy rate comparable to clinician-collected samples.
The study involved 3,068 women aged between 20 and 54 with regular menstrual cycles, who provided three samples for testing: a menstrual blood sample collected using a sanitary pad and strip, a cervical sample collected by a clinician, and an extra sample collected by a health worker. The researchers assessed the test's sensitivity and specificity, finding that while it performed less well on specificity, the probability of a person with a negative test result truly not having the disease was identical for both collection methods.
Experts are hailing this research as "pioneering" and "encouraging," with Cancer Research UK's Sophie Brooks saying that testing menstrual blood for HPV is an "interesting, non-invasive approach" that could potentially offer another option in the future. However, Bosch, an emeritus researcher at the Catalan Institute of Oncology, cautioned that it's still early days and more trials are needed to understand its clinical applications.
The Eve Appeal's Athena Lamnisos welcomed the findings, highlighting that new methods can be "more acceptable and potentially gentler" for women who may have barriers or concerns about traditional screening. However, she noted that this method would not work for everyone, particularly those in menopause.
The potential of this test lies in its ability to provide a choice of different screening methods for eligible women, addressing the issue of non-attendance rates at cervical screening programs. As researchers continue to explore and refine this innovative approach, it's clear that menstrual blood testing could be a significant step forward in preventing cervical cancer from developing.
In a groundbreaking study published in the BMJ medical journal, researchers have discovered that testing menstrual blood for signs of cervical cancer could be a game-changer in women's health. The innovative approach involves using a sanitary pad with a blood sample strip to detect human papillomavirus (HPV), which is responsible for most cases of cervical cancer.
Contrary to traditional methods where women undergo cervical screening under the care of a clinician, who collects a sample via a brush inserted into the vagina, this new test could provide a convenient and non-invasive alternative. According to the study, the menstrual blood test showed remarkable sensitivity and specificity in detecting cervical cell abnormalities (CIN2 and CIN3), with a 94.7% accuracy rate comparable to clinician-collected samples.
The study involved 3,068 women aged between 20 and 54 with regular menstrual cycles, who provided three samples for testing: a menstrual blood sample collected using a sanitary pad and strip, a cervical sample collected by a clinician, and an extra sample collected by a health worker. The researchers assessed the test's sensitivity and specificity, finding that while it performed less well on specificity, the probability of a person with a negative test result truly not having the disease was identical for both collection methods.
Experts are hailing this research as "pioneering" and "encouraging," with Cancer Research UK's Sophie Brooks saying that testing menstrual blood for HPV is an "interesting, non-invasive approach" that could potentially offer another option in the future. However, Bosch, an emeritus researcher at the Catalan Institute of Oncology, cautioned that it's still early days and more trials are needed to understand its clinical applications.
The Eve Appeal's Athena Lamnisos welcomed the findings, highlighting that new methods can be "more acceptable and potentially gentler" for women who may have barriers or concerns about traditional screening. However, she noted that this method would not work for everyone, particularly those in menopause.
The potential of this test lies in its ability to provide a choice of different screening methods for eligible women, addressing the issue of non-attendance rates at cervical screening programs. As researchers continue to explore and refine this innovative approach, it's clear that menstrual blood testing could be a significant step forward in preventing cervical cancer from developing.